Viral Genotyping Reference Laboratory, Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, EH16 4SA, UK.
Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, EH9 3JR, UK.
Microb Genom. 2023 Apr;9(4). doi: 10.1099/mgen.0.000991.
The ARTIC protocol uses a multiplexed PCR approach with two primer pools tiling the entire SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) genome. Primer pool updates are necessary for accurate amplicon sequencing of evolving SARS-CoV-2 variants with novel mutations. The suitability of the ARTIC V4 and updated V4.1 primer scheme was assessed using whole genome sequencing of Omicron from clinical samples using Oxford Nanopore Technology. Analysis of Omicron BA.1 genomes revealed that 93.22 % of clinical samples generated improved genome coverage at 50× read depth with V4.1 primers when compared to V4 primers. Additionally, the V4.1 primers improved coverage of BA.1 across amplicons 76 and 88, which resulted in the detection of the variant-defining mutations G22898A, A26530G and C26577G. The Omicron BA.2 sub-variant (VUI-22JAN-01) replaced BA.1 as the dominant variant by March 2022, and analysis of 168 clinical samples showed reduced coverage across amplicons 15 and 75. Upon further interrogation of primer binding sites, a mutation at C4321T [present in 163/168 (97 %) of samples] was identified as a possible cause of complete dropout of amplicon 15. Furthermore, two mutations were identified within the primer binding regions for amplicon 75: A22786C (present in 90 % of samples) and C22792T (present in 12.5 % of samples). Together, these mutations may result in reduced coverage of amplicon 75, and further primer updates would allow the identification of the two BA.2-defining mutations present in amplicon 75: A22688G and T22679C. This work highlights the need for ongoing surveillance of primer matches as circulating variants evolve and change.
ARTIC 方案采用多重 PCR 方法,使用两个引物池覆盖整个 SARS-CoV-2(严重急性呼吸系统综合征冠状病毒 2)基因组。对于具有新突变的不断进化的 SARS-CoV-2 变体,需要进行引物池更新以实现准确的扩增子测序。使用牛津纳米孔技术对临床样本中的奥密克戎进行全基因组测序,评估了 ARTIC V4 和更新的 V4.1 引物方案的适用性。对奥密克戎 BA.1 基因组的分析表明,与 V4 引物相比,V4.1 引物在 50× 读深度时可将 93.22%的临床样本的基因组覆盖度提高。此外,V4.1 引物提高了 BA.1 在 76 和 88 号扩增子上的覆盖度,从而检测到了变体定义突变 G22898A、A26530G 和 C26577G。奥密克戎 BA.2 亚变体(VUI-22JAN-01)于 2022 年 3 月取代 BA.1 成为主要变体,对 168 个临床样本的分析表明,15 和 75 号扩增子的覆盖度降低。在进一步检查引物结合位点时,发现 C4321T 突变(存在于 168/168(97%)的样本中)可能是导致 15 号扩增子完全缺失的原因。此外,在 75 号扩增子的引物结合区域还发现了两个突变:A22786C(存在于 90%的样本中)和 C22792T(存在于 12.5%的样本中)。这些突变可能导致 75 号扩增子的覆盖度降低,如果进一步更新引物,则可以识别出 75 号扩增子中存在的两个 BA.2 定义突变:A22688G 和 T22679C。这项工作强调了随着流行变异的不断进化和变化,需要持续监测引物匹配情况。